Form Breast Health Supplement to the Medication Inventory (WHI Extension Study)
|
|
- Hilary Sanders
- 5 years ago
- Views:
Transcription
1 154 - Breast Health Supplement to the Medication Inventory (WHI ID WHI Participant Common ID Col#1 F154DAYS Days since randomization or enrollment Col#2 Days since randomization or enrollment to receipt of form N Missing Min Max Mean Std Dev , F154VTYP Visit Type Col#3 3 Annual visit F154VY Visit Year Col#4 Visit year in which this form was collected. N Missing Min Max Mean Std Dev BCTAMOX Ever taken tamoxifen Col#5 Since your breast cancer diagnosis: Have you ever taken tamoxifen (Novadex)? 0 No 3, Yes 2, Don't know Missing BCTAMOXDUR How long taken tamoxifen Col#6 Since your breast cancer diagnosis: How long did you take or have you taken tamoxifen? 1 Less than 1 month months months years years or more years 1, Missing 3, BCRALOX Ever taken raloxifene Col#7 Since your breast cancer diagnosis: Have you ever taken raloxifene (Evista)? 0 No 5, Yes Don't know Missing Page 1 of 6
2 154 - Breast Health Supplement to the Medication Inventory (WHI BCRALOXDUR How long taken raloxifene Col#8 Since your breast cancer diagnosis: How long did you take or have you taken raloxifene? 1 Less than 1 month months months years years or more years Missing 5, BCTOREM Ever taken toremifene Col#9 Since your breast cancer diagnosis: Have you ever taken toremifene (Fareston)? 0 No 5, Yes Don't know Missing BCTOREMDUR How long taken toremifene Col#10 Since your breast cancer diagnosis: How long did you take or have you taken toremifene? 1 Less than 1 month months months years years or more years Missing 5, BCANAST Ever taken anastrozole Col#11 Since your breast cancer diagnosis: Have you ever taken anastrozole (Arimidex)? 0 No 4, Yes 1, Don't know Missing BCANASTDUR How long taken anastrozole Col#12 Since your breast cancer diagnosis: How long did you take or have you taken anastrozole? 1 Less than 1 month months months years years or more years Missing 4, Page 2 of 6
3 154 - Breast Health Supplement to the Medication Inventory (WHI BCEXEME Ever taken exemestane Col#13 Since your breast cancer diagnosis: Have you ever taken exemestane (Aromasin)? 0 No 5, Yes Don't know Missing BCEXEMEDUR How long taken exemestane Col#14 Since your breast cancer diagnosis: How long did you take or have you taken exemestane? 1 Less than 1 month months months years years or more years Missing 5, BCLETRO Ever taken letrozole Col#15 Since your breast cancer diagnosis: Have you ever taken letrozole (Femara)? 0 No 4, Yes Don't know Missing BCLETRODUR How long taken letrozole Col#16 Since your breast cancer diagnosis: How long did you take or have you taken letrozole? 1 Less than 1 month months months years years or more years Missing 4, BCSERM Ever taken other SERM or aromatase inhibitor Col#17 Since your breast cancer diagnosis: Have you ever taken any SERM or aromatase inhibitor that is not listed above or that you may not recall the name of? 0 No 5, Yes Don't know Missing BCSERMDUR How long taken this other SERM or aromatase inhibitor Col#18 Page 3 of 6
4 154 - Breast Health Supplement to the Medication Inventory (WHI Since your breast cancer diagnosis: How long did you take or have you taken this medication (other SERM or aromatase inhibitor)? 1 Less than 1 month months months years years or more years Missing 5, BCBNONE Barrier-did not experience any Col#19 exemestane, and letrozole)?: I did not experience any barriers to taking these medications. 0 No 2, Yes 3, BCBNOHEAR Barrier-never heard of these meds Col#20 exemestane, and letrozole)?: I have never heard of these medications. 0 No 4, Yes BCBNOINSUR Barrier-insurance would not cover these meds Col#21 exemestane, and letrozole)?: My health insurance would not cover these medications. 0 No 5, Yes BCBCOST Barrier-meds cost too much Col#22 exemestane, and letrozole)?: These medications or copayments cost too much. 0 No 4, Yes Page 4 of 6
5 154 - Breast Health Supplement to the Medication Inventory (WHI BCBGETTODR Barrier-problem getting to physician Col#23 exemestane, and letrozole)?: It is a problem for me to get to my facility/physician. 0 No 5, Yes BCBINCONV Barrier-taking these meds inconvenient Col#24 exemestane, and letrozole)?: Taking these medications would be inconvenient. 0 No 5, Yes BCBSIDEEFF Barrier-concerned about side effects Col#25 exemestane, and letrozole)?: I was concerned about possible side effects or complications from these medications. 0 No 4, Yes BCBWORK Barrier-concerned about missing work Col#26 exemestane, and letrozole)?: I was concerned about missing work due to taking these medications. 0 No 5, Yes BCBFAMILY Barrier-family discouraged me from taking Col#27 exemestane, and letrozole)?: My family discouraged me from taking these medications. 0 No 5, Yes Page 5 of 6
6 154 - Breast Health Supplement to the Medication Inventory (WHI BCBFRIEND Barrier-friends discouraged me from taking Col#28 exemestane, and letrozole)?: My friends discouraged me from taking these medications. 0 No 5, Yes BCBTOOMANY Barrier-taking too many meds Col#29 exemestane, and letrozole)?: I am taking too many medications. 0 No 5, Yes BCBDISLIKE Barrier-don't like taking meds Col#30 exemestane, and letrozole)?: I don't like taking medications. 0 No 4, Yes BCBNORECOM Barrier-physician didn't recommend these meds Col#31 exemestane, and letrozole)?: My physician did not recommend these medications for my particular type of breast disease. 0 No 3, Yes 1, BCBOTHER Barrier-other Col#32 exemestane, and letrozole)?: Other 0 No 4, Yes F154FINDYS Days since randomization or enrollment to form finish Col#33 N Missing Min Max Mean Std Dev 5, , Page 6 of 6
A Layperson's Guide to Endocrine (Hormone) Therapy
A Layperson's Guide to Endocrine (Hormone) Therapy What we will cover What is the endocrine system Basic definition of endocrine therapy Classes of endocrine drugs How you can utilise endocrine therapy
More informationA breast lump or thickening that feels different from the surrounding tissue
Breast Cancer Breast cancer is caused by abnormal cells that form in the breast tissue. Breast cancer is the most common cancer affecting South African women 1 in 35 women in South Africa will be diagnosed
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ibrance) Reference Number: CP.PHAR.125 Effective Date: 10.01.15 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationClinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17
Clinical Policy: (Tykerb) Reference Number: CP.PHAR.79 Effective Date: 10.01.11 Last Review Date: 11.17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationAfter skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.
Diseases and Conditions Breast cancer By Mayo Clinic Staff Breast cancer is cancer that forms in the cells of the breasts. After skin cancer, breast cancer is the most common cancer diagnosed in women
More informationSystemic Treatment of Breast Cancer. Hormone Therapy and Chemotherapy, Curative and Palliative
Systemic Treatment of Breast Cancer Hormone Therapy and Chemotherapy, Curative and Palliative Systemic Therapy Invasive breast cancers Two forms Curative Palliative Curative Systemic Therapy Adjuvant Therapy
More informationPrescribing of endocrine therapy after breast cancer diagnosis
Prescribing of endocrine therapy after breast cancer diagnosis Gabrielle Emanuel, Katherine E Henson, John Broggio, Jackie Charman, Kieran Horgan, David Dodwell, Sarah C Darby National Cancer Registration
More informationMOST Operations Manual page 1 MEDICATION INVENTORY
MOST Operations Manual page 1 TABLE OF CONTENTS MEDICATION INVENTORY 1. Background and rationale... 2 2. Equipment and supplies... 2 3. Detailed measurement procedures... 2 3.1 Drug definition guidelines...
More informationClinical Policy: Toremifene (Fareston) Reference Number: CP.PMN.126 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Fareston) Reference Number: CP.PMN.126 Effective Date: 04.01.10 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationAcknowledgement of Privacy Statement, Authorization and Assignments of Benefits. Release of Medical Information, Appointments and Prescriptions
Acknowledgement of Privacy Statement, Authorization and Assignments of Benefits Patients Name (Please print) Date of Birth Guarantor s Name (Please print) Date of Birth (If patient is a minor or dependent)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationBreast. Presentation Outline
Breast FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.02 Presentation Outline Overview Anatomy of Breast Multiple Primary
More informationBreast. FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.
Breast FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.02 Presentation Outline Overview Anatomy of Breast Multiple Primary
More informationArimidex and mushroom supplements bank of america line of credit payoff address rachael ray weight gain 2017
Arimidex and mushroom supplements bank of america line of credit payoff address rachael ray weight gain 2017 Totally unfiltered web search babita she gat mom lag time Sitemap Arimidex supplement. drink
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationClinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Perjeta) Reference Number: CP.PHAR.227 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the
More informationOSTEOPOROSIS ASSESSMENT CENTER
OSTEOPOROSIS ASSESSMENT CENTER BOARD CERTIFIED RHEUMATOLOGISTS HERBERT S.B. BARAF, MD FACP MACR DAVID G. BORENSTEIN, MD FACP FACR ASHLEY D. BEALL, MD FACR ROBERT L. ROSENBERG, MD FACR CCD ROBERT J. LLOYD,
More informationForm 35 - Personal Habits Update
File ame Sep 12, 25 Aug 29, 212 ID WHI Participant Common ID Col#1 F35DAYS F35 Days since randomization Col#2 4 3892 1,522.382 872.618 F35VTYP Visit Type Col#3 2 Semi-Annual visit 2. 3 Annual visit 173,399
More information4.7 Studies of Quality Holy Cross Hospital Bone Health Early Stage I ER/PR Positive Breast Cancer Patients December 13, 2017
4.7 Studies of Quality Holy Cross Hospital 2017 Bone Health Early Stage I ER/PR Positive Breast Cancer Patients December 13, 2017 Bone Health in Stage I ER/PR Positive Breast Cancer Patients To review
More informationStandard Breast Cancer Therapy
Pt s Who Don t Follow Treatment Standard Breast Cancer Therapy Deborah Thames R.T. (R)(M)(QM) Advancements in Breast Cancer Advancements in Breast Cancer Chemotherapy Full potential was recognized in the
More informationREFERENCE NUMBER: NH.PST.05 EFFECTIVE DATE: 10/10
PAGE: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationSupplementary Online Content
Supplementary Online Content Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. Published
More informationCancer Genetics Unit Patient Information
Chemoprevention for women at an increased risk of familial breast cancer Cancer Genetics Unit Patient Information What is chemoprevention? Chemoprevention describes drugs that are used to reduce the risk
More informationGynecologic Care for Breast Cancer Survivors. Case
Gynecologic Care for Breast Cancer Survivors Mindy Goldman, MD Clinical Professor Dept. of Ob/Gyn and Reproductive Sciences Director, Women s Cancer Care Program, UCSF Breast Care Center and Women s Health
More informationMedical Review. The following slides were medically reviewed by Dr. Nancy Dawson in June 2018.
Bone Health Medical Review The following slides were medically reviewed by Dr. Nancy Dawson in June 2018. Presentation Overview 1. What is bone health? 2. How can cancer and cancer treatments affect your
More informationSOUTH TEXAS FRACTURE PREVENTION CLINIC PRE-DEXA PATIENT QUESTIONNAIRE
OFFICE USE ONLY SOUTH TEXAS FRACTURE PREVENTION CLINIC PRE-DEXA PATIENT QUESTIONNAIRE PLACE STICKER HERE Name: Date of Birth: Male Female Primary Care Physician Name: Phone Number: Referring Physician
More informationThank you for calling the Osteoporosis Assessment Center to schedule your DEXA (bone mineral density study) appointment on.
Dear Patient: Thank you for calling the Osteoporosis Assessment Center to schedule your DEXA (bone mineral density study) appointment on. Enclosed you will find forms relating to our financial policy,
More informationSafe Handling of Oral Anti cancer Agents: Perspectives from Breast Cancer Patients at National Cancer Centre
Safe Handling of Oral Anti cancer Agents: Perspectives from Breast Cancer Patients at National Cancer Centre ABSTRACT Sim M.H. 1, Leow Y.C. 2 and Chan A. 3 Department of Pharmacy, Faculty of Science, National
More informationOPINION 3 April 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 April 2013 AFINITOR 5 mg, tablet B/30 (CIP: 34009 396 281 1 0) AFINITOR 10 mg, tablet B/30 (CIP: 34009 396 282 8
More informationBreast Cancer Prevention Studies. Key Points. Breast cancer prevention studies are clinical trials (research studies conducted with
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Breast Cancer Prevention
More informationHormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive
Hormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive breast cancer Issued: November 2006 guidance.nice.org.uk/ta112 NICE 2006 Contents 1 Guidance... 3 2 Clinical need and practice...
More informationIncreased Risk of Breast Cancer: Screening and Prevention. Elizabeth Pritchard, MD 4/5/2017
Increased Risk of Breast Cancer: Screening and Prevention Elizabeth Pritchard, MD 4/5/2017 No disclosures Defining Risk Risk Factors Modifiable Lifestyle obesity physical activity alcohol consumption breast
More informationW3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability
W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability Background: The key issue is to investigate whether some of the data
More informationForm 2 - Eligibility Screening
ID WHI Common ID Col#1 F2DAYS F2 Days since randomization Col#2 N Missing Min Max Mean Std Dev 0-1753 1107-145.472 153.960 F2CONT Contact type Col#3 The method used to collect the data. 1 Phone 65,083
More informationI have nothing to disclose
What s So Important about Specialized Gynecology Care after Breast Cancer? Mindy Goldman, MD Clinical Professor Dept. of Ob/Gyn and Reproductive Sciences Director, Women s Cancer Care Program, UCSF Breast
More informationBreast Cancer Prevention for the Population at Large
Breast Cancer Prevention for the Population at Large Jack Cuzick Centre for Cancer Prevention Wolfson Institute of Preventive Medicine St Bartholomew s Medical School Queen Mary University of London London,
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationDepartment of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada 3
he Cardiovascular Safety of Aromatase Inhibitors and amoxifen in Post-Menopausal Women with Breast Cancer: A Systematic eview and Meta-Analysis of andomized Controlled rials Farzin Khosrow-Khavar MSc 1,2,
More informationLecture 10: Hormonal agents
Lecture 10: Hormonal agents The survival and proliferation (growth) of some cancer cells is dependent on the action of steroid hormones. Early stage breast cancer and early stage prostate cancer are the
More informationUpdate from the 29th Annual San Antonio Breast Cancer Symposium
Update from the 29th Annual San Antonio Breast Cancer Symposium The San Antonio Breast Cancer Symposium is one of the most important breast cancer conferences. Approximately 8,000 physicians, oncologists,
More informationUse of Endocrine Therapy Data Points # 14
Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer Use of Endocrine Therapy Data Points # 14 In 212, approximately 23, women in the United States were
More informationBeyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO
Beyond the Break After Breast Cancer: Osteoporosis in Survivorship Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Disclosures No disclosures Osteoporosis in Breast Cancer Survivorship
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationBeing cancer-free does not mean being free of cancer 2/26/17. What s Next? Survivorship Care Following Cancer Treatment. What is Survivorship?
What s Next? Survivorship Care Following Cancer Treatment Kelli Cole-Vadjic, MS, PA-C Puget Sound Oncology Nursing Society 39 th Annual Oncology Nursing Symposium March 3, 2017 What is Survivorship? Survivor
More informationI have nothing to disclose. Mindy Goldman, MD. Case. Breast Cancer: What the Gynecologist Needs to Know
Breast Cancer: What the Gynecologist Needs to Know Mindy Goldman, MD Clinical Professor Dept. of Ob/Gyn and Reproductive Sciences Director, Women s Cancer Care Program, UCSF Breast Care Center and Women
More informationThe Latest Research: Hormonal Therapies
The Latest Research: Hormonal Therapies Sameer Gupta, M.D., M.P.H 9/29/2018 Attending Physician, Hematology/Oncology Bryn Mawr Hospital Clinical Assistant Professor, Jefferson Medical College Disclosures
More informationThe Pharmacist s Role in Breast Cancer Awareness and Treatment
The Pharmacist s Role in Breast Cancer Awareness and Treatment James A. Trovato, Pharm.D., BCOP Associate Professor University of Maryland School of Pharmacy This program has been supported by an educational
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationSection 5 Treatment and health service provision
Treatment and health service provision : Experience of treatment Treatments experienced The most common treatments were surgery (n=94, 94.00%) and Radiation therapy (n=79, 79.00%). This was followed by
More informationHypertension and diabetes treatments and risk of adverse outcomes among breast cancer patients. Lu Chen
Hypertension and diabetes treatments and risk of adverse outcomes among breast cancer patients Lu Chen A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy
More informationSo, Who are the appropriate individuals that should consider genetic counseling and genetic testing?
Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary
More informationSetting The setting was secondary care. The economic study was carried out in Canada.
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis Rocchi A, Verma S Record Status This is a critical
More informationSetting The study setting was secondary care. The economic study was carried out in Norway.
Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationAmerican Society of Clinical Oncology June , New Orleans
American Society of Clinical Oncology June 5-8 2004, New Orleans The 2004 annual meeting of the American Society of Clinical Oncology (ASCO) was held June 5 8 in New Orleans, Louisiana. This conference
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationBreast Cancer Treatments Breast surgery either breast conserving lumpectomy or modified mastectomy. May also include immediate or delayed reconstructi
The Gynecologic Implications of Breast Cancer Mindy Goldman, MD Clinical Professor Dept. of OB/Gyn and Reproductive Sciences Director, Women s Cancer Care Program, Carol Franc Buck Breast Care Center and
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationNorthumbria Healthcare NHS Foundation Trust. Your Guide to Endocrine Therapy. Issued by the Breast Team
Northumbria Healthcare NHS Foundation Trust Your Guide to Endocrine Therapy Issued by the Breast Team This leaflet is to explain about your endocrine therapy. Your guide to endocrine therapy There are
More informationBREAST CANCER RISK REDUCTION
BREAST CANCER RISK REDUCTION Clinical Practice Guideline Update Introduction ASCO published its first breast cancer risk reduction (BCRR) guideline in 1999 ASCO Guidelines are updated at intervals by an
More informationExtension Study 2, Self Reported, Non-Adjudicated Outcomes for MRC Participants
Extension Study 2, Self Reported, on-adjudicated Outcomes for s File ame A self report is only counted if the first report of that outcome occurred after the start of the extension 2 phase of the study.
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Overview
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Overview Hormonal therapies for the adjuvant treatment of early oestrogen-receptor positive breast cancer The overview is written by members of the
More informationSurviving Breast Cancer
Surviving Breast Cancer What to expect after completing treatment Dexter T. Estrada, MD Hematology Oncology Medical Group of Fresno, Inc. November 3, 2012 Epidemiology & Survival Estimates Breast cancer
More informationHormonal Therapies for Breast Cancer. Westmead Breast Cancer Institute
Hormonal Therapies for Breast Cancer Westmead Breast Cancer Institute Hormonal (endocrine) therapies for breast cancer (also called anti-hormone treatment ) Hormonal therapy is used to treat breast cancers
More informationForm 45 - Current Supplements
File ame Sep 12, 25 Aug 29, 212 ID WHI Participant Common ID Col#1 F45DAYS F45 Days since randomization/enrollment Col#2-595 3892 81.77 887.279 F45VTYP Visit Type Col#3 Value Description % 1 Screening
More informationBreast cancer has the highest incidence among those
Medical Treatment of Breast Cancer Young Seon Hong, M.D. Department of Internal Medicine Catholic University of Korea, St. Mary's Hospital E mail : y331@cmc.cuk.ac.kr Abstract Breast cancer has the highest
More informationThe Role of Aromatase Inhibitor (AI) in The Treatment of Breast Cancer
R E V I E W A R T I C L E The Role of Inhibitor (AI) in The Treatment of Breast Cancer Cosphiadi Irawan, Abdulmuthalib INTRODUCTION Discussion on the topic with the same title above would never be separated
More informationHealthcare Cost-Effectiveness Analysis for Older Patients: Using Cataract Surgery and Breast Cancer Treatment Data. Chapter 5
Healthcare Cost-Effectiveness Analysis for Older Patients: Using Cataract Surgery and Breast Cancer Treatment Data Chapter 5 Decision Analysis Modeling of the Adjuvant Treatment of Older Patients with
More informationBreast Cancer CANCERCARE CONNECT BOOKLET SERIES
CANCERCARE CONNECT BOOKLET SERIES Treatment Update Breast Cancer With Advances in the Treatment of HER2-Positive Breast Cancer and Highlights From the 2012 San Antonio Breast Cancer Symposium www.cancercare.org
More information/ NCCN. ACS (www.cancer.org) NCC (www.nccn.org) NCCN NCCN ACS ACS-2345
/2002 9 /2002 9 (NCCN) (ACS) NCCN ACS (www.cancer.org) NCC (www.nccn.org) NCCN 1-888-909-NCCN ACS 1-800-ACS-2345 NCCN ACS NCCN NCCN ACS NCCN 2002 (NCCN) (ACS) NCCN ACS ...................................
More informationThioredoxin and Jab1 Control Estrogen- and Antiestrogen-Mediated Progression of the Cell Cycle Through p27 Interactions
Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 3-11-2011 Thioredoxin and Jab1 Control Estrogen- and Antiestrogen-Mediated Progression
More informationFigure 1: PALLAS Study Schema. Endocrine adjuvant therapy may have started before randomization and be ongoing at that time.
Figure 1: PALLAS Study Schema Endocrine adjuvant therapy may have started before randomization and be ongoing at that time. Approximately 4600 patients from approximately 500 global sites will be randomized
More informationEvaluation & Management of PowerPoint Cover Title. the High Risk Population. High Risk Clinic
Evaluation & Management of PowerPoint Cover Title the High Risk Population High Risk Clinic Subtitle Joanna Would Springman, Go Here PA-C Assessment Genetics Known genetic mutation Family history with
More informationAnti-aromatase Agents in the Treatment and Prevention of Breast Cancer
Based on their activity in the metastatic setting, anti-aromatase agents are now being evaluated in the adjuvant setting and in pilot studies for chemoprevention. Michele Sassi. La Digue Island, c. 2001.
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
More informationPopulation: All participants Number of Obs: Variable # Sas Name: Sas Label: Categories: Variable # Sas Name: F43VNUM. Sas Label: Categories:
Data File: form4dat Last Update: 04/6/00 umber of Obs: 6809 Participant ID ID Participant ID Study: Administration F4 Days since randomization/enrollment 04-595 7-504 59476 F4DAYS F4 Days since randomization/enrollment
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationBreast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States.
Dr. Andrew Seidman s Commentary I. Breast Cancer Overview Breast cancer remains the most common malignancy and the second leading cause of cancer mortality in women in the United States. The following
More informationWomen s Health: Breast Cancer Screening. K. Rast, MD and E. McNany, MD
Women s Health: Breast Cancer Screening K. Rast, MD and E. McNany, MD 2013 2017 Update: Who? How? When? Cases and Practice Questions Question 1 A 40 year old female comes to your office for a well woman
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationART Drugs. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.02 Subject: ART Drugs Page: 1 of 7 Last Review Date: December 3, 2015 ART Drugs Description Bravelle
More informationForm 2023 R2.0: Ovarian Cancer Pre-HSCT Data
Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationAccess To Cancer Drugs In Medicare Part D: Formulary Placement And Beneficiary Cost Sharing In 2006
Access To Cancer Drugs In Medicare Part D: Formulary Placement And eneficiary Cost Sharing In 2006 Medicare Part D beneficiaries have access to many more cancer drugs than ever before, with low cost sharing.
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationPOSITION PAPER FOR HEALTH CARE PROVIDERS Use of Pharmacologic Intervention for Breast Cancer Risk Reduction
P.O. Box 30195 Lansing, MI 48909 Phone: 877-588-6224 FAX: 517-335-9397 www.michigancancer.org Introduction POSITION PAPER FOR HEALTH CARE PROVIDERS Use of Pharmacologic Intervention for Breast Cancer Risk
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationRisk Assessment, Genetics, and Prevention
Risk Assessment, Genetics, and Prevention Katherine D. Crew, MD MS Director, Clinical Breast Cancer Prevention Program Columbia University Medical Center 1 Outline Breast cancer risk factors Hereditary
More informationGiuseppe Viale for the BIG 1 98 Collaborative and International Breast Cancer Study Groups
Central Review of ER, PgR and HER2 in BIG 1 98 Evaluating Letrozole vs. Letrozole Tamoxifen vs. Tamoxifen Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor Positive
More informationA review of adjuvant hormonal therapy in
REVIEW Endocrine-Related Cancer (2004) 11 391 406 A review of adjuvant hormonal therapy in breast cancer Kellie L Jones and Aman U Buzdar 1 Department of Pharmacy, University of Texas M.D. Anderson Cancer
More informationThe Estrogen Question
The Estrogen Question Hormone Therapy still offers the best relief for menopausal symptoms. Is it right for you? When 49-year-old Lee Ann Dodson heard the news that the Women's Health Initiative (WHI)
More informationART Drugs. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.02 Subject: ART Drugs Page: 1 of 7 Last Review Date: September 15, 2017 ART Drugs Description Bravelle
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More information